Please assess the completion status of the following clinical trial:

Trial Title: Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of primary brain tumor or brain metastases, meeting 1 of the following criteria:~  * No radiographic evidence of disease~ * Stable disease, defined as no tumor progression within the past 3 months~* Previously treated with 1 course of localized or whole brain radiotherapy of at least 3,000 cGy at least 6 months before study registration~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 70-100%~Life expectancy~* At least 30 weeks~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Other~* Not pregnant or nursing~* Negative pregnancy test~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No concurrent chemotherapy~Endocrine therapy~* Concurrent steroid therapy allowed if on stable or decreasing dose~Radiotherapy~* See Disease Characteristics~* No concurrent cranial radiotherapy~Surgery~* No concurrent surgery~Other~* More than 3 months since prior donepezil or EGb761~* No concurrent donepezil (group 2 only)~* No concurrent EGb761 (group 1 only) (closed to accrual 10/09/03)~* No concurrent anticoagulants (e.g., aspirin, dipyridamole, heparin, warfarin, or enoxaparin) (group 2 only)~* No concurrent monoamine oxidase inhibitors (e.g., phenelzine or tranylcypromine)~* No other concurrent therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).